Genzyme cutting jobs at newly-acquired Bone Care

Just weeks after completing a deal to buy Bone Care International for $719 million, Genzyme announced it will hand out pink slips to about 40 employees. Most of the workers had been employed in various administrative duties. Genzyme says it plans to retain Bone Care's laboratory facility and most of its scientists. Bone Care sold a drug that restores kidney patients' vitamin D levels.

- read this report in the Milwaukee Journal-Sentinel for more

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.